Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral L-Carnitine Supplementation in Cardiorenal Heart Failure Patients
NCT07201714Phase 1Recruiting
- Start
- Nov 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of levocarnitine in heart failure (HF) and carnitine deficiency. Primary endpoints: Recruitment Rate at 52 weeks, Retention Rate at 6 months and 3 more. Started Nov 2025; status: recruiting.
02
Drugs
levocarnitine
03
Conditions
heart failure (HF)carnitine deficiency
Beyond the preview
Go deeper on NCT07201714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07201714.